HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 133 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2014. The put-call ratio across all filers is 1.38 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $692,131,092 | +3.1% | 18,118,615 | -2.6% | 0.02% | +11.1% |
| Q2 2023 | $671,064,060 | -3.2% | 18,604,493 | +2.5% | 0.02% | -10.0% |
| Q1 2023 | $692,990,086 | -33.1% | 18,145,852 | -0.4% | 0.02% | -37.5% |
| Q4 2022 | $1,036,474,809 | +44.0% | 18,215,726 | +0.1% | 0.03% | +33.3% |
| Q3 2022 | $719,614,000 | -11.0% | 18,199,633 | -1.0% | 0.02% | -7.7% |
| Q2 2022 | $808,782,000 | +3.1% | 18,381,405 | -6.6% | 0.03% | +23.8% |
| Q1 2022 | $784,449,000 | +0.4% | 19,670,225 | +1.2% | 0.02% | +5.0% |
| Q4 2021 | $781,676,000 | -0.4% | 19,439,863 | +0.7% | 0.02% | -9.1% |
| Q3 2021 | $784,935,000 | -9.3% | 19,295,380 | +1.2% | 0.02% | -8.3% |
| Q2 2021 | $865,808,000 | +12.6% | 19,066,438 | +3.4% | 0.02% | +4.3% |
| Q1 2021 | $768,660,000 | -2.6% | 18,437,478 | -0.2% | 0.02% | -8.0% |
| Q4 2020 | $789,337,000 | +127.4% | 18,481,307 | +39.9% | 0.02% | +92.3% |
| Q3 2020 | $347,138,000 | -2.2% | 13,209,235 | -0.2% | 0.01% | -7.1% |
| Q2 2020 | $354,786,000 | +62.4% | 13,233,306 | +8.9% | 0.01% | +27.3% |
| Q1 2020 | $218,520,000 | +1.9% | 12,146,804 | +0.4% | 0.01% | +37.5% |
| Q4 2019 | $214,477,000 | +6.3% | 12,096,797 | -7.0% | 0.01% | 0.0% |
| Q3 2019 | $201,701,000 | -7.0% | 13,004,538 | +3.0% | 0.01% | -11.1% |
| Q2 2019 | $216,900,000 | +15.2% | 12,625,128 | +8.0% | 0.01% | +12.5% |
| Q1 2019 | $188,292,000 | +9.5% | 11,695,148 | -0.5% | 0.01% | -11.1% |
| Q4 2018 | $171,991,000 | -20.3% | 11,756,120 | -1.1% | 0.01% | 0.0% |
| Q3 2018 | $215,886,000 | +4.5% | 11,881,526 | -2.9% | 0.01% | -10.0% |
| Q2 2018 | $206,530,000 | -9.0% | 12,242,431 | +5.7% | 0.01% | -9.1% |
| Q1 2018 | $226,905,000 | -7.4% | 11,582,668 | -4.2% | 0.01% | -8.3% |
| Q4 2017 | $245,025,000 | +16.0% | 12,094,021 | -0.6% | 0.01% | +9.1% |
| Q3 2017 | $211,295,000 | +42.1% | 12,164,375 | +4.9% | 0.01% | +37.5% |
| Q2 2017 | $148,652,000 | +3.7% | 11,595,500 | +4.8% | 0.01% | 0.0% |
| Q1 2017 | $143,374,000 | +9600.5% | 11,062,842 | +7292.8% | 0.01% | +300.0% |
| Q4 2016 | $1,478,000 | +459.8% | 149,643 | +584.7% | 0.00% | – |
| Q3 2016 | $264,000 | +45.1% | 21,856 | +3.8% | 0.00% | – |
| Q2 2016 | $182,000 | +171.6% | 21,061 | +197.9% | 0.00% | – |
| Q1 2016 | $67,000 | +26.4% | 7,070 | +129.8% | 0.00% | – |
| Q4 2015 | $53,000 | +1.9% | 3,077 | -19.2% | 0.00% | – |
| Q3 2015 | $52,000 | -24.6% | 3,809 | +24.5% | 0.00% | – |
| Q2 2015 | $69,000 | +46.8% | 3,060 | -5.5% | 0.00% | – |
| Q1 2015 | $47,000 | +51.6% | 3,238 | 0.0% | 0.00% | – |
| Q4 2014 | $31,000 | +6.9% | 3,238 | 0.0% | 0.00% | – |
| Q3 2014 | $29,000 | -9.4% | 3,238 | 0.0% | 0.00% | – |
| Q2 2014 | $32,000 | -22.0% | 3,238 | -0.5% | 0.00% | – |
| Q1 2014 | $41,000 | -12.8% | 3,255 | +4.3% | 0.00% | – |
| Q4 2013 | $47,000 | +30.6% | 3,120 | -4.3% | 0.00% | – |
| Q3 2013 | $36,000 | +38.5% | 3,260 | 0.0% | 0.00% | – |
| Q2 2013 | $26,000 | – | 3,260 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |